Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: Solid-state characterization and aerosol dispersion performance

Drug Development and Industrial Pharmacy

Volumn 41, Issue 9, 2015, Pages 1431-1437

  Dolatabadi, Jafar Ezzati Nazhad ^a,b   Hamishehkar, Hamed ^c   Valizadeh, Hadi ^b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alendronate; Dry powder inhaler; Fine particle fraction; Solid lipid nanoparticle

Indexed keywords

ALENDRONIC ACID; MANNITOL; SOLID LIPID NANOPARTICLE; AEROSOL; BONE DENSITY CONSERVATION AGENT; LIPID; NANOPARTICLE;

AEROSOL; ANGLE OF REPOSE; AQUEOUS SOLUTION; ARTICLE; DISPERSION; DRUG FORMULATION; DRY POWDER; DRY POWDER INHALER; EMULSION; HAUSNER RATIO; IN VITRO STUDY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SPRAY DRYING; CHEMISTRY; DRUG DELIVERY SYSTEM; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PROCEDURES;

ADMINISTRATION, INHALATION; AEROSOLS; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; LIPIDS; MANNITOL; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES;

EID: 84964265512     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.956111     Document Type: Article

References (44)

1. Miladi K, Sfar S, Fessi H, Elaissari A. Drug carriers in osteoporosis: Preparation, drug encapsulation and applications. Int J Pharm 2013; 445: 181-95.
2. Gupta VK, Jain R, Sharma S, et al. Quantitative determination of alendronate in human urine. Int J Electrochem Sci 2012; 7: 569-87.
3. Ezzati Nazhad Dolatabadi J, Hamishehkar H, de la Guardia M, Valizadeh H. A fast and simple spectrofluorometric method for the determination of alendronate sodium in pharmaceuticals. BioImpacts 2014; 4: 39-42.
4. Sultana S, Ali R, Talegaonkar S, et al. In vivo lung deposition and sub-acute inhalation toxicity studies of nano-sized alendronate sodium as an antidote for inhaled toxic substances in Sprague Dawley rats. Environ Toxicol Pharm 2013; 36: 636-47.
5. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999; 13: 515-9.
6. Marshall JK, Rainsford KD, James C, Hunt RH. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 2000; 14: 1451-7.
7. Lanza F. Bisphosphonate mucosal injury-The end of the story? Dig Liver Dis. (2003 35: 67-70.
8. Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
9. Karie S, Launay-Vacher V, Izzedine H, Deray G. [Drud-induced nephrotoxicity: Bibliography from January 2003 to December 2005]. Nephrol Ther 2006; 2: 368-78.
10. Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Assessment methods of inhaled aerosols: Technical aspects and applications. Expert Opin Drug Deliv 2009; 6: 941-59.
11. Jaafar-Maalej C, Elaissari A, Fessi H. Lipid-based carriers: Manufacturing and applications for pulmonary route. Expert Opin Drug Deliv 2012; 9: 1111-27.
12. Sutton SC, Engle K, Fix JA. Intranasal delivery of the bisphosphonate alendronate in the rat and dog. Pharm Res 1993; 10: 924-6.
13. Varshosaz J, Taymouri S, Hamishehkar H. Fabrication of polymeric nanoparticles of poly(ethylene-co-vinyl acetate) coated with chitosan for pulmonary delivery of carvedilol. J Appl Polym Sci 2014; 131. doi: 10.1002/app.39694.
14. Sultana S, Talegaonkar S, Ali R, et al. Inhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosis. J Microencapsul 2012; 29: 445-54.
15. Hamishehkar H, Emami J, Najafabadi AR, et al. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin. Int J Pharm 2010; 389: 74-85.
16. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Resp Care 2005; 50: 1209-27.
17. Saint-Lorant G, Leterme P, Gayot A, Flament MP. Influence of carrier on the performance of dry powder inhalers. Int J Pharm 2007; 334: 85-91.
18. Cruz L, Fattal E, Tasso L, et al. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J Control Release 2011; 152: 370-5.
19. Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H. Beclomethasoneloaded lipidic nanocarriers for pulmonary drug delivery: Preparation, characterization and in vitro drug release. J Nanosci Nanotechnol 2011; 11: 1841-51.
20. Rostami E, Kashanian S, Azandaryani AH, et al. Drug targeting using solid lipid nanoparticles. Chem Phys Lipids 2014; 181: 56-61.
21. Mü ller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
22. Souto EB, Wissing SA, Barbosa CM, Mü ller RH. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J Pharm Biopharm 2004; 58: 83-90.
23. Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012; 47: 139-51.
24. Ezzati Nazhad Dolatabadi J, Hamishehkar H, Eskandani M, Valizadeh H. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 2014; 117: 21-8.
25. Eskandani M, Nazemiyeh H. Self-reporter shikonin-act-loaded solid lipid nanoparticle: Formulation, physicochemical characterization and geno/cytotoxicity evaluation. Eur J Pharm Sci 2014; 59: 49-57.
26. Kashanian S, Rostami E. PEG-stearate coated solid lipid nanoparticles as levothyroxine carriers for oral administration. J Nanopart Res 2014; 16: 1-10.
27. Bose S, Du Y, Takhistov P, Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems. Int J Pharm 2013; 441: 56-66.
28. Mussi SV, Silva RC, Oliveira MCd, et al. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 2013; 48: 282-90.
29. Pilpel N. The flow properties of magnesia. J Pharm Pharmacol 1964; 16: 705-16.
30. Carr R. Evaluating flow properties of solids. Chem Eng 1965; 72: 163-8.
31. Carr R. Classifying flow properties of solids. Chem Eng 1965; 72: 69-72.
32. Bosquillon C, Lombry C, Préat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 2001; 70: 329-39.
33. Chougule M, Padhi B, Misra A. Development of spray dried liposomal dry powder inhaler of dapsone. AAPS PharmSciTech 2008; 9: 47-53.
34. Ahmad MZ, Akhter S, Ahmad I, et al. In vitro and in vivo evaluation of Assam Bora rice starch-based bioadhesive microsphere as a drug carrier for colon targeting. Expert Opin Drug Deliv 2012; 9: 141-9.
35. Zhao M, You Y, Ren Y, et al. Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spraydrying. Powder Technol 2008; 187: 214-21.
36. Kramek-Romanowska K, Odziomek M, Sosnowski TR, Gradoń L. Effects of process variables on the properties of spray-dried mannitol and mannitol/disodium cromoglycate powders suitable for drug delivery by inhalation. Ind Eng Chem Res 2011; 50: 13922-31.
37. Littringer EM, Noisternig MF, Mescher A, et al. The morphology and various densities of spray dried mannitol. Powder Technol 2013; 246: 193-200.
38. Rahimpour Y, Hamishehkar H. Lactose engineering for better performance in dry powder inhalers. Adv Pharm Bull 2012; 2: 183-7.
39. Kho K, Hadinoto K. Dry powder inhaler delivery of amorphous drug nanoparticles: Effects of the lactose carrier particle shape and size. Powder Technol 2013; 233: 303-11.
40. Pilcer G, Wauthoz N, Amighi K. Lactose characteristics and the generation of the aerosol. Adv Drug Deliv Rev 2012; 64: 233-56.
41. Wan F, You J, Sun Y, et al. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): Preparation and evaluation in vitro. Int J Pharm 2008; 359: 104-10.
42. Kaialy W, Martin GP, Ticehurst MD, et al. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. Int J Pharm 2010; 392: 178-88.
43. Maas SG, Schaldach G, Littringer EM, et al. The impact of spray drying outlet temperature on the particle morphology of mannitol. Powder Technol 2011; 213: 27-35.
44. Mansour HM, Xu Z, Hickey AJ. Dry powder aerosols generated by standardized entrainment tubes from alternative sugar blends: 3. Trehalose dihydrate and D-mannitol carriers. J Pharm Sci 2010; 99: 3430-41.